ArticleACS applied materials & interfaces2025
Scalable Biofabrication of Functional 3D Scaffolds via Synergy of Autopilot Single-Jet Electrospun 3D PCL Fiber Scaffolds and Cell-Laden Hydrogels.
Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Controlling 3D Contractility via Engineered Fibrous Hydrogel Composites.Advanced functional materials · 2026Article
- Quantitative Assessment of Hydrogel Printability in Extrusion Bioprinting.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting enables cell-laden hydrogel construct fabrication in a layer-by-layer fashion but faces scalability challenges due to the mechanical weakness of hydrogels. Matrix reinforcement compromises cellular activity, creating a scalability-functionality trade-off that remains unresolved as sophisticated strategies including sequential and embedded printing fail to effectively overcome these limitations. This study presents an alternative approach by integrating autopilot single-jet electrospun (AJ-3D ES) 3D PCL fiber scaffolds with hydrogels, achieving anatomical precision, mechanical robustness, and enhanced cell function. Hydrogel dip-coating of anatomically structured PCL scaffolds enabled organ-scale cellular constructs. By providing an ECM-mimicking porous fiber network, embedded cells mitigated the limitations of hydrogel stiffness (even ∼50 kPa) and facilitated cell-cell interactions, supporting epithelialization, fibroblast clustering, and 3D phase-separated HepG2-HUVEC co-cultures. Contour 3D bioprinting along PCL fiber scaffold topographies facilitated endothelial patterning for vascularization and native-tissue mimicking complexity. Volumetric scalability was demonstrated through hydrogel casting, embedded bioprinting, and modular stacking within 3D PCL fiber scaffolds, ensuring hydrogel integrity while maintaining medium diffusion for sustained cell survival and function. In vivo studies confirmed the proangiogenic nature of PCL fiber scaffolds with tissue bridging via cell infiltration and ECM collagen deposition, underscoring clinical translational potential. By integrating topographic and volumetric flexibility, this approach advances biofabrication strategies for functional tissue and organ constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.